PZ0116

PD-166285 hydrate

≥98% (HPLC)

• 同義詞: 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride hydrate
• 經驗公式（希爾表示法）: C₂₆H₂₇Cl₂N₅O₂·2HCl
• 分子量：: 585.35
• MDL號碼: MFCD17215957
• 分類程式碼代碼: 51111800
• PubChem物質ID: 329823708
• NACRES: NA.77

屬性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: yellow
• 溶解度: DMSO: ≥20 mg/mL; H₂O: ≥5 mg/mL
• 儲存溫度: room temp
• SMILES 字串: O.Cl.Cl.CCN(CC)CCOc1ccc(Nc2ncc3C=C(C(=O)N(C)c3n2)c4c(Cl)cccc4Cl)cc1
• InChI: 1S/C26H27Cl2N5O2.2ClH.H2O/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H;1H2
• InChI 密鑰: FHIIMEXCWLFXBU-UHFFFAOYSA-N

描述

應用

PD-166285 Hydrate has been used as a fibroblast growth factor (FGF) signaling inhibitor to study its effects on LIM-homeodomain gene 9 (Lhx9) expression during limb development in mice.

生化／生理作用

PD-166285 is also a potent inhibitor of Wee-1, epidermal growth factor receptor, and platelet-derived growth factor receptor β subunit (PDGFR-β). It also exhibits its inhibitory effects against mitogen-activated protein kinase (MAPK) and protein kinase C (PKC). PD-166285 shows antiproliferative and anti-migratory effects due to which it may be used as a therapeutic agent against atherosclerosis, restenosis, and cancer.

PD-166285 hydrate is a broad spectrum protein tyrosine kinase inhibitor; Src and FGFR kinase inhibitor.

特點和優勢

This compound is featured on the FGFR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

安全資訊

• 象形圖: GHS06
• 訊號詞: Danger
• 危險聲明: H301,H413
• 防範說明: P264 - P270 - P273 - P301 + P310 - P405 - P501
• 危險分類: Acute Tox. 3 Oral - Aquatic Chronic 4
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable